Bethany A Horsburgh, Eunok Lee, Bonnie Hiener, John-Sebastian Eden, Timothy E Schlub, Susanne von Stockenstrom, Lina Odevall, Jeffrey M Milush, Teri Liegler, Elizabeth Sinclair, Rebecca Hoh, Eli A Boritz, Daniel C Douek, Remi Fromentin, Nicolas Chomont, Steven G Deeks, Frederick M Hecht, Sarah Palmer
OBJECTIVE: The contribution of HLA-DR+ memory CD4+ T-cells to the HIV reservoir during prolonged antiretroviral therapy is unclear as these cells are commonly excluded when assessing for replication-competent HIV. To address this issue, we examined the distribution of genetically intact HIV DNA within HLA-DR- and HLA-DR+ memory CD4 T-cells and the RNA transcriptional profile of these cells during ART. DESIGN/METHODS: Full-length DNA sequencing was used to examine the HIV DNA landscape within HLA-DR+ and HLA-DR- memory CD4+ T-cells...
January 6, 2020: AIDS
Abena Kr Kwaa, Caroline C Garliss, Kristen D Ritter, Gregory M Laird, Joel N Blankson
: Elite controllers or suppressors (ES) control viral replication without antiretroviral therapy (ART). We used the intact proviral DNA assay to approximate the size of the inducible latent reservoir in ES and found that while the median frequency of both total and intact proviral DNA was markedly lower than the frequencies seen in chronic progressors (CP) on ART, there was no significant difference in the ratio of intact to total proviral DNA between ES and CP.
December 27, 2019: AIDS
Mounerou Salou, Christelle Butel, Adjo S Comlan, Abla A Konou, Kokou Tegueny, Amivi Ehlan, Fiali Lack, Sika Dossim, Ahidjo Ayouba, Eric Delaporte, Anoumou Y Dagnra, Martine Peeters
OBJECTIVE: Evaluate the potential effectiveness of the implementation of DTG-based regimens in patients on failing current ART given the high levels of NRTI resistance in Togo. DESIGN: Patients on ART attending health facilities for routine follow-up visits and for whom HIV viral load (VL) test was performed were consecutively included. METHODS: Protease, Reverse Transcriptase (RT) and Integrase fragments were sequenced and analyzed for presence of drug resistance mutations (DRMs) for patients with VL > 1,000 copies/mL...
December 27, 2019: AIDS
Robert H Paul, Kyu S Cho, Andrew C Belden, Claude A Mellins, Kathleen M Malee, Reuben N Robbins, Lauren E Salminen, Stephen J Kerr, Badri Adhikari, Paola M Garcia-Egan, Jiratchaya Sophonphan, Linda Aurpibul, Kulvadee Thongpibul, Pope Kosalaraksa, Suparat Kanjanavanit, Chaiwat Ngampiyaskul, Jurai Wongsawat, Saphonn Vonthanak, Tulathip Suwanlerk, Victor G Valcour, Rebecca N Preston-Campbell, Jacob D Bolzenious, Merlin Robb, Jintanat Ananworanich, Thanyawee Puthanakit
OBJECTIVE: To develop a predictive model of neurocognitive trajectories in children with perinatal HIV (pHIV). DESIGN: Machine learning analysis of baseline and longitudinal predictors derived from clinical measures utilized in pediatric HIV. METHODS: 285 children (ages 2-14 years at baseline; Mage = 6.4 years) with pHIV in Southeast Asia underwent neurocognitive assessment at study enrollment and twice annually thereafter for an average of 5...
December 27, 2019: AIDS
Mirella Carr, Robyn Richardson, Winnie Tong, Mark Bloch, David Baker, Jennifer F Hoy
: Integrase inhibitor-based antiretroviral therapy (INSTI-ART) can cause weight gain. It is unknown if this is a class effect, with limited data regarding raltegravir. In 37 virologically suppressed adults (36 men, mean age 49 years) who switched from tenofovir disoproxil fumarate to raltegravir 400 mg twice daily, mean weight changes from baseline at Weeks 24, 48 and 96 were not significant (maximum 0.8 kg at Week 24; all p≥0.16). Weight gain may not occur with all INSTIs.
December 27, 2019: AIDS
Chris Delcher, Jungjun Bae, Shannan N Rich, Emily M Klann, Nancy Puttkammer, Nadjy Joseph
OBJECTIVE: To evaluate the impact of the January 12, 2010 earthquake on HIV cases from Haiti's national HIV surveillance system and assess the characteristics of people living with HIV one-year before and after the earthquake. DESIGN: An interrupted time-series design and cross-sectional analysis METHODS:: We used Autoregressive Integrated Moving Average (ARIMA) structures to model abrupt changes to the monthly, incident HIV case counts from HIV care clinics as reported to the Haitian Active Longitudinal Tracking of HIV System (French acronym SALVH) by clinical networks (n = 3) and earthquake instrumental intensity zones (n = 4)...
December 27, 2019: AIDS
Arianne Y K Albert, Chelsea Elwood, Emily C Wagner, Zahra Pakzad, Tessa Chaworth-Musters, Kyra Berg, Julie Van Schalkwyk, Evelyn J Maan, Arezou Azampanah, Elisabeth Mcclymont, Ariane Alimenti, John C Forbes, Deborah M Money
OBJECTIVE: To investigate factors contributing to preterm birth (PTB), including cART use and clinical and social determinants of health, in women living with HIV (WLWH) from British Columbia, Canada. DESIGN: Retrospective observational cohort. METHODS: We investigated the effect of cART use and other clinical and demographic factors on spontaneous PTB (sPTB) rates (<37 weeks gestational age) among 631 singleton pregnancies between 1997-2018...
December 27, 2019: AIDS
Jenell Stewart, Elizabeth Bukusi, Connie Celum, Sinead Delany-Moretlwe, Jared M Baeten
No abstract text is available yet for this article.
December 27, 2019: AIDS
Jingrong Ye, Mingqiang Hao, Hui Xing, Fujie Zhang, Hao Wu, Wei Lv, Tianjun Jiang, Yuncong Wang, Juan Wang, Yi Feng, Ruolei Xin, Ji Zeng, Shuai Zhao, Yinxiao Hao, Jing Chen, Yuhua Ruan, Xue Li, Yiming Shao, Hongyan Lu
OBJECTIVES: Fifteen years after the roll-out of antiretroviral treatment (ART) in China, there is limited information available on transmitted HIV drug resistance (TDR). This study aimed to characterize the epidemiology of TDR in China. DESIGN: We conducted a prospective cross-sectional observational study. METHODS: We analyzed the demographic, clinical, and virological data of individuals with newly diagnosed HIV infection using data from the Beijing HIV laboratory network collected between 2001 and 2017...
December 27, 2019: AIDS
Maarten Reitsema, Albert Jan Van Hoek, Maarten Schim Van Der Loeff, Elske Hoornenborg, Ard Van Sighem, Jacco Wallinga, Birgit Van Benthem, Maria Xiridou
OBJECTIVES: To assess the impact of a pre-exposure prophylaxis (PrEP) programme for high-risk men who have sex with men (MSM), which includes gonorrhoea testing and treatment, on the transmission of HIV and N. gonorrhoeae among MSM in the Netherlands and the cost-effectiveness of such programme with and without risk compensation (in the form of reduced condom use). METHODS: We developed a stochastic agent-based transmission model of HIV and gonorrhoea. We simulated a capped (max 2...
December 27, 2019: AIDS
Caroline Besson, Nicolas Noel, Remi Lancar, Sophie Prevot, Michele Algarte-Genin, Eric Rosenthal, Fabrice Bonnet, Marie-Caroline Meyohas, Marialuisa Partisani, Lucie Oberic, Jean Gabarre, Cécile Goujard, Antoine Cheret, Cedric Arvieux, Christine Katlama, Dominique Salmon, François Boué, Regis Costello, Houria Hendel-Chavez, Yassine Taoufik, Hélène Fontaine, Paul Coppo, Nicolas Mounier, Pierre Delobel, Dominique Costagliola
OBJECTIVE: Chronic hepatitis C virus (HCV) and hepatitis virus (HBV) infections are associated with increased risks of lymphomas in the non-HIV setting. Their impacts on HIV-associated lymphomas deserved further studies in the modern combined antiretroviral therapy (cART) era. DESIGN: We evaluated the associations between HCV, HBV and HIV-related lymphomas in the Lymphovir-ANRS-CO16 cohort. METHODS: Prevalence of HCV-seropositivity and chronic HBV infections were compared to those observed in the French Hospital Database on HIV (FHDH-ANRS-CO4)...
December 10, 2019: AIDS
Chloe Orkin, Joseph J Eron, Jürgen Rockstroh, Daniel Podzamczer, Stefan Esser, Linos Vandekerckhove, Erika Van Landuyt, Erkki Lathouwers, Veerle Hufkens, John Jezorwski, Magda Opsomer
BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10mg was investigated through 96 weeks in AMBER (NCT02431247). METHODS: Treatment-naïve, HIV-1-positive adults (screening plasma viral load [VL]≥1000 copies/ml; CD4 count >50 cells/mm) were randomized (1:1) to D/C/F/TAF (N=362) or D/C plus emtricitabine/tenofovir-disoproxil-fumarate (F/TDF) (N=363) over ≥48 weeks. After week 48, patients could continue on or switch to D/C/F/TAF in an open-label extension phase until week 96...
December 10, 2019: AIDS
Selamawit A Woldesenbet, Tendesayi Kufa, Peter Barron, Brian C Chirombo, Mireille Cheyip, Kassahun Ayalew, Carl Lombard, Samuel Manda, Karidia Diallo, Yogan Pillay, Adrian J Puren
OBJECTIVE: To describe viral load (VL) levels among pregnant women and factors associated with failure to achieve viral suppression (VL≤50 copies/mL) (VS) during pregnancy. DESIGN: Between 1 October and 15 November 2017, a cross-sectional survey was conducted among 15-49 year old pregnant women attending antenatal care (ANC) in 1,595 nationally representative public facilities. METHODS: Blood specimens were taken from each pregnant woman and tested for HIV...
December 9, 2019: AIDS
Thomas A Angelovich, Janine M Trevillyan, Jennifer F Hoy, Michelle E Wong, Paul A Agius, Anna C Hearps, Anthony Jaworowski
OBJECTIVE: People living with HIV have an increased risk of cardiovascular disease (CVD) despite effective antiretroviral therapy (ART). Monocytes play a key role in the early stages of atherosclerosis-driven CVD by forming lipid-laden foam cells within artery walls. HIV infection potentiates foam cell formation ex vivo, but the mechanisms contributing to this are not known. METHODS: We investigated the atherosclerosis-promoting potential of monocytes from 39 virologically suppressed men living with HIV (MLHIV) on ART and no evidence of CVD, and 25 HIV-uninfected controls of comparable age, sex, smoking status and CVD risk...
December 5, 2019: AIDS
Olivia Briceño, Monserrat Chávez-Torres, Amy Peralta-Prado, Daniela Garrido-Rogríguez, Karla Romero-Mora, Sandra Pinto-Cardoso, Gustavo Reyes-Terán
OBJECTIVE: Around 20-30% of HIV-infected subjects (HIV+) on successful antiretroviral therapy (ART) fail to normalize their CD4+ T cell counts. Various factors could contribute to the lack of immune reconstitution (IR), one of them being thymic insufficiency. We aimed to explore associations between recent thymic emigrants (RTEs) and CD4+ T cell recovery. DESIGN: ART-naïve HIV+ subjects who started ART with advanced AIDS were selected. Good versus poor IR was defined by CD4 gains above or below 100 CD4+ T cells/mm...
December 2, 2019: AIDS
Simon B Ascher, Rebecca Scherzer, Michelle M Estrella, Judy Shigenaga, Kimberly A Spaulding, David V Glidden, Megha L Mehrotra, Patricia Defechereux, Monica Gandhi, Robert M Grant, Michael G Shlipak, Vasantha Jotwani
OBJECTIVE: To evaluate the effects of HIV preexposure prophylaxis (PrEP) with tenofovir disoproxial fumurate (TDF)/emtricitabine (FTC) on kidney function and kidney tubular health. DESIGN: The Iniciativa Profilaxis Pre-Exposicion open-label extension (iPrEx-OLE) study enrolled former PrEP trial participants to receive open-label TDF/FTC. This study included 123 iPrEx-OLE participants who demonstrated PrEP adherence. METHODS: We compared estimated glomerular filtration rate calculated using serum creatinine (eGFRcr), serum cystatin C (eGFRcys), and in combination (eGFRcr-cys), and a panel of 14 urine biomarkers reflecting kidney tubular health before and 6 months after PrEP initiation...
December 2, 2019: AIDS
Qiang Xia, Joel O Wertheim, Sarah L Braunstein, Kavita Misra, Chi-Chi Udeagu, Lucia V Torian
BACKGROUND: To develop a predictive model to prioritize persons with a transmissible HIV viral load for transmission-reduction interventions. METHODS: New York City (NYC) HIV molecular surveillance data from 2010 to 2013 were used to build a model to predict the probability that the partial pol gene of the virus of a person with a transmissible HIV viral load (>1500 copies/ml) would be genetically similar to that of a person with a new HIV infection (diagnosis at stage 0 or 1 according to the revised Centers for Disease Control and Prevention classification system)...
December 2, 2019: AIDS
Emanuel Krebs, Xiao Zang, Benjamin Enns, Jeong E Min, Czarina N Behrends, Carlos Del Rio, Julia C Dombrowski, Daniel J Feaster, Kelly A Gebo, Matthew Golden, Brandon D L Marshall, Lisa R Metsch, Bruce R Schackman, Steven Shoptaw, Steffanie A Strathdee, Bohdan Nosyk
OBJECTIVE: Effective interventions to reduce the public health burden of HIV/AIDS can vary in their ability to deliver value at different levels of scale and in different epidemiological contexts. Our objective was to determine the cost-effectiveness of HIV treatment and prevention interventions implemented at previously documented scales of delivery in six US cities with diverse HIV microepidemics. DESIGN: Dynamic HIV transmission model-based cost-effectiveness analysis...
December 2, 2019: AIDS
Peter W Young, Emily Zielinski-Gutierrez, Joyce Wamicwe, Irene Mukui, Andrea A Kim, Anthony Waruru, Clement Zeh, Mirjam E Kretzschmar, Kevin M De Cock
OBJECTIVE: To compare alternative methods of adjusting self-reported knowledge of HIV-positive status and antiretroviral (ARV) therapy use based on undetectable viral load (UVL) and ARV detection in blood. DESIGN: Post hoc analysis of nationally representative household survey to compare alternative biomarker-based adjustments to population HIV indicators. METHODS: We reclassified HIV-positive participants aged 15-64 years in the 2012 Kenya AIDS Indicator Survey (KAIS) that were unaware of their HIV-positive status by self-report as aware and on antiretroviral treatment if either ARVs were detected or viral load was undetectable (<550 copies/ml) on dried blood spots...
December 2, 2019: AIDS
Fatima Kakkar, Terry Lee, Michael T Hawkes, Jason Brophy, Samson Lindy, Joel Singer, Hinatea Dieumegard, Laura Sauve, Ariane Alimenti, Wendy Vaudry, Sandra Seigel, Ben Tan, Christos Karatzios, Valerie Lamarre, Stanley Read, Hugo Soudeyns, Ari Bitnun
OBJECTIVES: The objective of this study was to determine the time to, and durability of, viral suppression, among Canadian children living with HIV after initiation of combination antiretroviral therapy (cART). DESIGN: Prospective, multicenter Canadian cohort study (Early Pediatric Initiation Canada Child Cure Cohort), using both prospective and retrospectively collected data. METHODS: Kaplan-Meir survival estimates with Cox regression were used to determine the time to and risk factors for viral suppression, defined as two consecutive undetectable viral loads (<50 copies/ml) at least 30 days apart after initiation of cART...
December 2, 2019: AIDS
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"